Press Releases

Year

May 27 2026

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

New $14.99 -per-month membership brings together free and low-cost generic medications, affordable online care visits, and savings across dental, vision, labs and imaging Brief Summary: GoodRx launched GoodRx Companion, a new $14.99 -per-month subscription to lower everyday healthcare costs

PDF Version

May 06 2026

GoodRx Reports First Quarter 2026 Results

Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter Company Raises Full Year 2026 Revenue and Adjusted EBITDA Expectations SANTA MONICA, Calif. --(BUSINESS WIRE)--May 6, 2026-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading

PDF Version

May 01 2026

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

Eligible self-pay patients can access the oral diabetes treatment for as low as $149 per month Brief Summary: GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month Available at GoodRx’s nationwide pharmacy network Adds an oral option to the Ozempic treatment

PDF Version

Apr 17 2026

GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call

SANTA MONICA, Calif. --(BUSINESS WIRE)--Apr. 17, 2026-- GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S.

PDF Version

Apr 15 2026

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss Brief Summary: Wegovy® HD is now available on GoodRx at a self-pay price of $399 per month Pricing scales to $798 for two-month supply and $1,197 for three-month supply

PDF Version

Apr 09 2026

GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx Brief Summary: GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron) Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx

PDF Version

Mar 11 2026

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc® SANTA MONICA, Calif. --(BUSINESS WIRE)--Mar. 11, 2026-- GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today

PDF Version

Mar 06 2026

GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®

GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs Brief Summary: GoodRx to collaborate with Eli Lilly to expand employer-sponsored access to Zepbound® KwikPen®, an

PDF Version

Feb 25 2026

GoodRx Reports Fourth Quarter and Full Year 2025 Results

Fourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous Guidance Pharma Direct Revenue Beats Previous Outlook with Over 40% Year-Over-Year Growth for 2025 SANTA MONICA, Calif. --(BUSINESS WIRE)--Feb. 25, 2026-- GoodRx Holdings, Inc.

PDF Version

Feb 24 2026

GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”

New program combines employer-subsidized discounted cash prices and custom telemedicine solutions with existing health benefits to close coverage gaps and support access to high-impact medications SANTA MONICA, Calif. --(BUSINESS WIRE)--Feb. 24, 2026-- GoodRx (Nasdaq: GDRX), the leading platform

PDF Version

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

Press Releases

site - Investor Tools